{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:19:30Z","timestamp":1790943570909,"version":"4.1.0"},"reference-count":57,"publisher":"Microbiology Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,1]]},"abstract":"<jats:p>A humanized monoclonal antibody (mAb) has been developed and its potential to protect from or cure a Venezuelan equine encephalomyelitis virus (VEEV) infection was evaluated. The VEEV-neutralizing, protective murine mAb 3B4C-4 was humanized using combinatorial antibody libraries and phage-display technology. Humanized VEEV-binding Fabs were evaluated for virus-neutralizing capacity, then selected Fabs were converted to whole immunoglobulin (Ig) G1, and stable cell lines were generated. The humanized mAb Hy4-26C, designated Hy4 IgG, had virus-neutralizing capacity similar to that of 3B4C-4. Passive antibody protection studies with purified Hy4 IgG were performed in adult Swiss Webster mice. As little as 100\u2005ng Hy4 IgG protected 90\u200a% of mice challenged with 100 intraperitoneal (i.p.) mean morbidity (MD<jats:sub>50<\/jats:sub>) doses of virulent VEEV (Trinidad donkey) 24\u2005h after antibody transfer; also, 500\u2005\u03bcg Hy4 IgG protected 80\u200a% of mice inoculated with 100 intranasal MD<jats:sub>50<\/jats:sub>doses of VEEV. Moreover, 10\u2005\u03bcg passive Hy4 IgG protected 70\u200a% of mice from a VEEV challenge dose as great as 10<jats:sup>7<\/jats:sup>i.p. MD<jats:sub>50<\/jats:sub>. Hy4 IgG also protected mice from challenge with another epizootic VEEV variety, 1C (P676). Importantly, therapeutic administration of the humanized mAb to mice already infected with VEEV cured 90\u200a% of mice treated with Hy4 IgG within 1\u2005h of VEEV inoculation and 75\u200a% of mice treated 24\u2005h after virus infection.<\/jats:p>","DOI":"10.1099\/vir.0.81925-0","type":"journal-article","created":{"date-parts":[[2006,8,7]],"date-time":"2006-08-07T21:02:46Z","timestamp":1154984566000},"page":"2467-2476","source":"Crossref","is-referenced-by-count":53,"title":["A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus"],"prefix":"10.1099","volume":"87","author":[{"given":"Ann R.","family":"Hunt","sequence":"first","affiliation":[{"name":"Arbovirus Diseases Branch, Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, PO Box 2087, Fort Collins, CO 80522, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana","family":"Frederickson","sequence":"additional","affiliation":[{"name":"Alexion Antibody Technologies, San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hinkel","sequence":"additional","affiliation":[{"name":"Alexion Antibody Technologies, San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine S.","family":"Bowdish","sequence":"additional","affiliation":[{"name":"Alexion Antibody Technologies, San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Roehrig","sequence":"additional","affiliation":[{"name":"Arbovirus Diseases Branch, Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, PO Box 2087, Fort Collins, CO 80522, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","volume-title":"Phage Display: a Laboratory Manual","author":"Barbas","year":"2001"},{"key":"R2","first-page":"209","article-title":"Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea-pig heart cells","volume":"73","author":"Berge","year":"1961","journal-title":"Am J Hyg"},{"key":"R3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00000441-200206000-00004","article-title":"Viral agents as biological weapons and agents of bioterrorism","volume":"323","author":"Bronze","year":"2002","journal-title":"Am J Med Sci"},{"key":"R4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/136.3.354","article-title":"Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine","volume":"136","author":"Burke","year":"1977","journal-title":"J Infect Dis"},{"key":"R5","first-page":"1421","article-title":"Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia","volume":"4","author":"Caron","year":"1998","journal-title":"Clin Cancer Res"},{"key":"R6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2144\/01302bm02","article-title":"Scaling up the ligase chain reaction-based approach to gene synthesis","volume":"30","author":"Chalmers","year":"2001","journal-title":"Biotechniques"},{"key":"R7","first-page":"371","article-title":"Study of homologous and heterologous antibody response in California horses vaccinated with attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83)","volume":"39","author":"Ferguson","year":"1978","journal-title":"Am J Vet Res"},{"key":"R8","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/JCM.10.4.544-549.1979","article-title":"Neutralizing antibody responses of humans and mice to vaccination with Venezuelan encephalitis (TC-83) virus","volume":"10","author":"Fillis","year":"1979","journal-title":"J Clin Microbiol"},{"key":"R9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0022-2836(92)91010-M","article-title":"Antibody framework residues affecting the conformation of the hypervariable loops","volume":"224","author":"Foote","year":"1992","journal-title":"J Mol Biol"},{"key":"R10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R11","first-page":"7","article-title":"The health and economic impact of Venezuelan equine encephalitis (VEE","volume-title":"In Venezuelan Encephalitis","author":"Groot","year":"1972"},{"key":"R12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0264-410X(96)00204-6","article-title":"Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB\/c, but not C3H\/HeN mice","volume":"15","author":"Hart","year":"1997","journal-title":"Vaccine"},{"key":"R13","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1128\/JVI.78.7.3325-3332.2004","article-title":"Isolation of human monoclonal antibodies that neutralize human rotavirus","volume":"78","author":"Higo-Moriguchi","year":"2004","journal-title":"J Virol"},{"key":"R14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"key":"R15","first-page":"79","article-title":"Venezuelan equine encephalitis","volume":"18","author":"Johnson","year":"1974","journal-title":"Adv Vet Sci Comp Med"},{"key":"R16","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J Infect Dis"},{"key":"R17","first-page":"843","article-title":"Alphaviruses","volume-title":"In Fields Virology","author":"Johnstone","year":"1995"},{"key":"R18","article-title":"Sequences of Proteins of Immunological Interest","volume-title":"Department of Health and Health Services","author":"Kabat","year":"1991"},{"key":"R19","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1073\/pnas.88.10.4363","article-title":"Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces","volume":"88","author":"Kang","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R20","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-04-0294","article-title":"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I\/II clinical trial results","volume":"10","author":"Leonard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R21","first-page":"100","article-title":"History and geographic distribution of Venezuelan equine encephalitis","volume":"8","author":"Lord","year":"1974","journal-title":"Bull Pan Am Health Organ"},{"key":"R22","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J Virol"},{"key":"R23","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.4049\/jimmunol.129.6.2763","article-title":"Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies","volume":"129","author":"Mathews","year":"1982","journal-title":"J Immunol"},{"key":"R24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/JVI.55.3.594-600.1985","article-title":"Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies","volume":"55","author":"Mathews","year":"1985","journal-title":"J Virol"},{"key":"R25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/348552a0","article-title":"Phage antibodies: filamentous phage displaying antibody variable domains","volume":"348","author":"McCafferty","year":"1990","journal-title":"Nature"},{"key":"R26","first-page":"369","article-title":"Inactivated and live VEE vaccines \u2013 a review","volume-title":"In Venezuelan Encephalitis","author":"McKinney","year":"1972"},{"key":"R27","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/JVI.78.9.4665-4674.2004","article-title":"Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus","volume":"78","author":"Men","year":"2004","journal-title":"J Virol"},{"key":"R28","first-page":"597","article-title":"Togaviruses, bunyaviruses, and Colorado tick fever","volume-title":"In Handbook of Clinical Microbiology","author":"Monath","year":"1976"},{"key":"R29","first-page":"331","article-title":"Togaviral diseases of domestic animals","volume-title":"In Comparative Diagnosis of Viral Diseases","author":"Monath","year":"1981"},{"key":"R30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.molimm.2005.04.002","article-title":"Humanization of chicken monoclonal antibody using phage-display system","volume":"43","author":"Nishibori","year":"2006","journal-title":"Mol Immunol"},{"key":"R31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1128\/JVI.19.3.985-997.1976","article-title":"Structural proteins of La Crosse virus","volume":"19","author":"Obijeski","year":"1976","journal-title":"J Virol"},{"key":"R32","doi-asserted-by":"crossref","first-page":"9532","DOI":"10.1128\/JVI.75.19.9532-9537.2001","article-title":"Venezuelan equine encephalomyelitis virus structure and its divergence from old world alphaviruses","volume":"75","author":"Paredes","year":"2001","journal-title":"J Virol"},{"key":"R33","first-page":"195","article-title":"The anti-viral activity of antibodies in vitro and in vivo","volume-title":"In Advances in Immunology","author":"Parren","year":"2001"},{"key":"R34","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1128\/JVI.76.12.6408-6412.2002","article-title":"Pre- and postexposure prophylaxis for Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody","volume":"76","author":"Parren","year":"2002","journal-title":"J Virol"},{"key":"R35","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0264-410X(01)00505-9","article-title":"Monoclonal antibody protects mice against infection and disease when given either before or up to 24\u2005h after airborne challenge with virulent Venezuelan equine encephalitis virus","volume":"20","author":"Phillpotts","year":"2002","journal-title":"Vaccine"},{"key":"R36","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1128\/JVI.74.12.5667-5678.2000","article-title":"The surface conformation of Sindbis virus glycoproteins E1 and E2 at neutral and low pH, as determined by mass spectrometry-based mapping","volume":"74","author":"Phinney","year":"2000","journal-title":"J Virol"},{"key":"R37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"key":"R38","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.1073\/pnas.95.15.8910","article-title":"A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries","volume":"95","author":"Rader","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R39","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1074\/jbc.275.18.13668","article-title":"The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies","volume":"275","author":"Rader","year":"2000","journal-title":"J Biol Chem"},{"key":"R40","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1086\/513978","article-title":"Epidemic Venezuelan equine encephalitis in La Guajira","volume":"175","author":"Rivas","year":"1997","journal-title":"J Infect Dis"},{"key":"R41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0042-6822(85)90343-5","article-title":"The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes","volume":"142","author":"Roehrig","year":"1985","journal-title":"Virology"},{"key":"R42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0042-6822(80)90481-X","article-title":"Isolation and characterization of hybrid cell lines producing monoclonal antibodies directed against the structural proteins of Sindbis virus","volume":"101","author":"Roehrig","year":"1980","journal-title":"Virology"},{"key":"R43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0042-6822(82)90346-4","article-title":"Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies","volume":"118","author":"Roehrig","year":"1982","journal-title":"Virology"},{"key":"R44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0042-6822(88)90659-9","article-title":"In vitro mechanisms of monoclonal antibody neutralization of alphaviruses","volume":"165","author":"Roehrig","year":"1988","journal-title":"Virology"},{"key":"R45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0079-6603(08)60893-4","article-title":"Development of more efficacious antibodies for medical therapy and diagnosis","volume":"60","author":"Santos","year":"1998","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"R46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.1696028","article-title":"Searching for peptide ligands with an epitope library","volume":"249","author":"Scott","year":"1990","journal-title":"Science"},{"key":"R47","first-page":"221","article-title":"Equine diseases","volume-title":"In Venezuelan Encephalitis","author":"Sharman","year":"1972"},{"key":"R48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0022-1759(84)90046-2","article-title":"Determination of blood volume in the mouse with 51chromium-labelled erythrocytes","volume":"73","author":"Sluiter","year":"1984","journal-title":"J Immunol Methods"},{"key":"R49","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1126\/science.4001944","article-title":"Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface","volume":"228","author":"Smith","year":"1985","journal-title":"Science"},{"key":"R50","doi-asserted-by":"crossref","first-page":"36073","DOI":"10.1074\/jbc.M002765200","article-title":"Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization","volume":"275","author":"Steinberger","year":"2000","journal-title":"J Biol Chem"},{"key":"R51","first-page":"1","article-title":"Rapid gene synthesis using ampligase thermostable DNA ligase","volume":"2","author":"Sutton","year":"1995","journal-title":"Epicentre Forum"},{"key":"R52","first-page":"266","article-title":"Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo","volume":"9","author":"Tempest","year":"1991","journal-title":"Biotechnology"},{"key":"R53","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4049\/jimmunol.157.2.772","article-title":"Isolation of neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning","volume":"157","author":"Tsui","year":"1996","journal-title":"J Immunol"},{"key":"R54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymeth.2005.01.007","article-title":"Design of humanized antibodies: from anti-Tac to Zenapax","volume":"36","author":"Tsurushita","year":"2005","journal-title":"Methods"},{"key":"R55","first-page":"1509","article-title":"Epizootiology of Venezuelan equine encephalomyelitis in the Americas","volume":"161","author":"Walton","year":"1972","journal-title":"J Am Vet Med Assoc"},{"key":"R56","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/00007890-199909150-00003","article-title":"Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma (Ala-Ala) in the treatment of acute renal allograft rejection","volume":"68","author":"Woodle","year":"1999","journal-title":"Transplantation"},{"key":"R57","doi-asserted-by":"crossref","first-page":"11645","DOI":"10.1128\/JVI.76.22.11645-11658.2002","article-title":"Placement of the structural proteins of Sindbis virus","volume":"76","author":"Zhang","year":"2002","journal-title":"J Virol"}],"container-title":["Journal of General Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.81925-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T12:23:26Z","timestamp":1683548606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.81925-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9,1]]}},"URL":"https:\/\/doi.org\/10.1099\/vir.0.81925-0","relation":{},"ISSN":["0022-1317","1465-2099"],"issn-type":[{"value":"0022-1317","type":"print"},{"value":"1465-2099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,1]]}}}